Comparative efficacy of modified-live and inactivated vaccines in boosting disease-sparing responses to bovine viral diarrhea virus challenge in neonatally mucosally primed weanling beef calves

Objective

This study compares immune and clinical responses of bovine viral diarrhea virus (BVDV)-maternal antibody (MatAb)-positive beef calves primed with intranasal modified-live virus vaccine (MLV) and differentially boosted with a systemic MLV or an inactivated vaccine (KV).

Animal

Eighteen commercial Black Angus steers.

Procedure

Calves were mucosally primed at ~24 h of age with an MLV and boosted by injection of a MLV (IN-MLV) or inactivated vaccine (IN-KV) at an average age of 54 d. Challenge occurred at weaning with a virulent non-cytopathic BVDV-2 strain, 24515.

Results

Clinically, the IN-KV group had a longer duration of fever, leukopenia, and viremia, whereas the IN-MLV group had greater BVDV Types-1 and -2 heterospecific antibody responses.

Conclusion

Altogether, these data indicated that systemic MLV boosting resulted in a more robust protection to BVDV Type-2 challenge at weaning.

Clinical relevance

Mucosal prime-boosting of neonatal calves provided protection against BVDV Type-2 challenge at weaning.

Infection of calves with in-vivo passaged bovine parainfluenza-3 virus, alone or in combination with bovine respiratory syncytial virus and bovine coronavirus

Bovine respiratory disease complex is etiologically complex and usually involves co-infection by several agents, including bovine parainfluenza virus-3 (BPIV-3), bovine respiratory syncytial virus (BRSV), and bovine coronavirus (BCoV). Traditionally, vaccines have been tested in seronegative calves infected with a single in vitro-passaged agent, often with little disease, resulting in unvaccinated subjects. To overcome the potential problem of attenuation coincident with in vitro culture of the viruses, cocktails of field isolates of BPIV-3s and BCoVs were passaged in the lungs of neonatal colostrum-deprived calves. Lung lavage fluids were used as inocula, alone and in combination with in-vivo passaged BRSV, and aerosolized into a trailer containing conventionally reared 9-week-old weaned Holstein calves with decayed, but still measurable, maternal antibodies. Calves developed acute respiratory disease of variable severity. Upon necropsy, there were characteristic gross and histologic lesions in the respiratory tract, associated immunohistochemically with BPIV-3, BRSV, and BCoV. In-vivo passage of viruses is an alternative to in vitro culture to produce inocula to better study the pathogenesis of infection and more rigorously and relevantly assess vaccine efficacy.

Frequency of Escherichia coli virotypes in calf diarrhea and intestinal morphologic changes associated with these virotypes or other diarrheagenic pathogens

Calf diarrhea is a common cause of pre-weaning morbidity and mortality in cattle operations. We evaluated the role of Escherichia coli by assessing the frequency of genes encoding virulence factors (virotypes) in E. coli from feces or intestinal contents, and the association of these virotypes or other diarrheagenic pathogens with intestinal morphologic changes in calves with or without diarrhea. E. coli was isolated from 408 feces and 105 intestines of calves with diarrhea and compared to those isolated from 635 feces and 100 intestines of calves without diarrhea, from 2002 to 2016. Virotype EAST1:F17, in combination with minor virotypes, was the most commonly detected type, but without differences in frequency between the 2 groups of calves. No significant intestinal morphologic changes were observed with the different E. coli virotypes in either group of calves, except for bacterial attachment to enterocytes for virotype STa:F5, which was detected only in calves with diarrhea. These observations suggest that E. coli, excluding virotype STa:F5, is not a significant diarrhea-causing agent in calves. However, the intestinal lesions observed in ~82% of calves with diarrhea were attributed to other diarrheagenic pathogens that include bovine coronavirus, Clostridium perfringens, Cryptosporidium spp., Eimeria spp., rotavirus, and Salmonella spp.

An unusual lipomatous brain mass in a Golden Retriever dog

A 9-year-old Golden Retriever dog was presented to the Veterinary Medical Center with a 3-week history of grand mal seizures and was subsequently euthanized. At autopsy, a discrete, firm, expansile mass was found in the right pyriform lobe, which compressed the ipsilateral hippocampus, thalamus, and cerebral cortex. Histologically, the mass was composed of well-differentiated adipose tissue supported by fibrous and mucinous stroma. Adipocytes exhibited strong immunoreactivity for vimentin and were negative for pancytokeratin (AE1/AE3), glial fibrillary acidic protein, neuron-specific enolase, and synaptophysin. These findings are most compatible with an intracranial lipomatous hamartoma, which is an extraparenchymal lesion that has been identified in several species. The current report describes an intracerebral lipomatous hamartoma in a veterinary species.

Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas

Feline viral plaques (FVP) induced by papillomavirus (PV) are often hyperpigmented and flat warts. The fact that up to 47% of bowenoid in situ carcinomas (BISC), which also usually occur in the form of hyperpigmented plaques, are positive for PV antigen in immunochemistry suggests that BISC could evolve from FVP. The relationship between the presence of PV antigens and the clinical and histological features of 26 cases of feline dermatoses (clinically described as pigmented plaques and with histological diagnosis of FVP and/or BISC) was therefore determined. The cases were classified into one of the three following groups: FVP, FVP + BISC or BISC. Immunohistological detection of papillomavirus group-specific antigen was performed using a polyclonal rabbit antibovine papillomavirus antiserum. Of the seven cases in the FVP group, six were deemed positive by immunohistology as were all 10 cats in the FVP + BISC group. On the other hand, only one of the nine BISC cats was positive. The presence of both FVP and BISC lesions in some cats and the high detection rate of PV antigens in the FVP and FVP + BISC groups suggest that both conditions might have the same viral cause and that some BISC may evolve from FVP. The low rate of viral antigen detection in the BISC group indicates another cause or a loss of viral replication during the cancerogenesis.

Cytokine profiles following interaction between bovine alveolar macrophages and Pasteurella haemolytica

Pasteurella haemolytica is a gram negative bacterium frequently isolated from the lungs of calves suffering from a fibrinous pneumonic condition known as shipping fever. To understand the pathogenesis of this disease, we investigated the induction of cytokin gene expression in cultures of bovine alveolar macrophages (BAM) stimulated with heat-killed P. haemolytica. Northern blot analysis of total RNA showed that P. haemolytica induced early, abundant, and consistent synthesis of IL-1, TNF-alpha, and IL-8 mRNA. Cytokine mRNAs were detected within 1 hr post-stimulation with heat-killed P. haemolytica. IL-1 and IL-8 mRNA accumulated to high levels with increase in stimulation time, whereas TNF-alpha mRNA clearly declined by 4 and 8 h post stimulation. IL-1, TNF-alpha, and IL-8 proteins were also secreted into the culture medium of BAM stimulated with heat-killed P. haemolytica. All three proteins were detected at high levels 8 and 12 h post stimulation with P. haemolytica. BAM cells treated with bovine interferon-alpha and then stimulated with P. haemolytica produced higher amounts of IL-1, IL-8 and TNF-alpha proteins compared to BAM stimulated with P. haemolytica alone. These findings demonstrate the powerful and selective induction of cytokine mRNA and protein synthesis in BAM stimulated with heat-killed P. haemolytica and may explain certain aspects of shipping fever pathogenesis.

Molecular cloning and expression of bovine interleukin-8

Interleukin-8 (IL-8) is a neutrophil and T-lymphocyte chemotactic and activating factor. This cytokine is produced by many cell types including macrophages in response to a variety of microbial and non-microbial agents. In the present study, we determined the nucleotide sequence for bovine IL-8 cDNA. The amino acid sequence encoded by this cDNA shares 76 and 87% homology with the human and swine IL-8 proteins, respectively. Bovine IL-8 cDNA was expressed in Escherichia coli as a beta-galactosidase fusion protein. Western blotting demonstrates that this fusion protein, but not beta-galactosidase cross-reacts with monospecific anti-human IL-8 antiserum. We also studied the induction of IL-8 mRNA synthesis in bovine alveolar macrophages (BAM) stimulated with heat-killed Pasteurella haemolytica. IL-8 mRNA was induced in BAM as early as 1 h and was detectable at high levels 12 h post-stimulation with P. haemolytica. A dose titration of P. haemolytica and E. coli endotoxins showed that a relatively low level of P. haemolytica endotoxin induced high levels of bovine IL-8 mRNA. The significance of these findings in the pathogenesis of bovine pneumonia caused by P. haemolytica is discussed.

The role of biological response modifiers in disease control

Immune responses to infectious agents involve a complex set of interactions between cells and the factors they produce that culminate with disease resolution or death. Therefore, the manipulation of the immune system may have a great impact on the preservation and restoration of animal health. Biological response modifiers are agents that modify the host's response to pathogens with resultant beneficial prophylactic or therapeutic effects. The best known example of biological response modifiers are vaccines, by which administration of a nonpathogenic form of a microorganism prepares the immune system to produce a more effective response upon subsequent infection with the pathogenic form. Nevertheless, the use of biological response modifiers other than vaccines that enhance the immune response is now the focus of many investigations. In this review, a brief overview of the immune system is presented, and special emphasis is placed on possible areas of intervention with biological response modifiers and a description of the prophylactic and therapeutic potential of biological response modifiers. Specific examples are presented to demonstrate examples of disease modification by biological response modifiers through stimulation of nonspecific and antigen specific immunities.

Capture immunoassay for ruminant tumor necrosis factor-alpha: comparison with bioassay

Monoclonal antibodies and IgG purified from rabbit polyclonal antiserum, raised against recombinant bovine tumor necrosis factor-alpha (TNF-alpha), have been employed in ELISA procedures to quantitate bovine TNF-alpha. These antibodies were potent in neutralizing the biological activity of recombinant as well as natural bovine TNF-alpha. The monoclonal antibodies were used as capture antibodies and were either passively adsorbed or covalently linked to ELISA plates. Polyclonal rabbit anti-TNF IgG was used as the detecting antibody in combination with a biotinylated anti-rabbit serum and a streptavidin-horseradish peroxidase conjugate. The detection limit for recombinant TNF-alpha medium was 10 pg ml-1 and in bovine or ovine serum was 35 pg ml-1. A good correlation was found between the ELISA and the WEHI-164 Clone 13 biologic assay when TNF-alpha was measured in medium containing serum or in serum. This capture ELISA was also capable of detecting ovine, but not porcine. TNF in supernatants from cultures of lipopolysaccharide-stimulated pulmonary alveolar macrophages.

Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV

Interleukin-2 has been described as an effective adjuvant for a number of antigens in different host species. Previously, we demonstrated the adjuvant activity of recombinant bovine IL-2 with a glycoprotein IV (gIV) subunit vaccine from bovine herpesvirus type-1 (BHV-1). In the present study, primary antibody responses were assessed in cattle immunized with either 2 or 50 micrograms of gIV, and treated with multiple doses of IL-2 or combinations of IL-2 and IFN-alpha or IL-2 and IFN-gamma. IL-2 was able to augment significantly antibody responses detected by either ELISA or virus neutralization. More significantly, IL-2 was able to enhance antibody titres in animals immunized with only 2 micrograms gIV to levels similar to those immunized with 50 micrograms gIV in the absence of IL-2. For optimal stimulation, multiple injections of IL-2 and Avridine had to be used in the formulation; other oil adjuvants or IL-2 alone could not induce a primary serum antibody response. Addition of IFN-alpha or IFN-gamma to the IL-2/gIV/Avridine formulation did not affect any of the immune parameters tested. As IFN-alpha is an effective immunoprophylactic agent for infectious bovine rhinotracheitis (IBR), combination vaccine-immunoprophylaxis may become feasible using IL-2 as a co-adjuvant. Thus, extremely low doses of antigen and only one immunization may be an effective vaccine given in combination with interferon prophylactic treatment.